1. Scrip
  2. >>Business

Commercial Models Shifting As Pharma Mulls Digital-First Launches

 
• By Anju Ghangurde

Pharma is assessing digital-first launch strategies amid COVID-19 while a resizing of sales forces and the emergence of "digital orchestrators" may also be in store, the co-founder of healthcare solutions provider Indegene tells Scrip.  

Digital World
Shift In Pharma Commercial Models Underway? • Source: Shutterstock

Significant shifts in pharma’s commercial model may be in store as firms both big and small evaluate digital-first launch approaches and re-size sales teams while co-opting new roles in the challenging business environment emerging after the coronavirus pandemic.

Gaurav Kapoor, co-founder and executive vice-president (global product commercialization) of Indegene, a global provider of healthcare solutions to the industry, outlined to Scrip how companies are now thinking of brand...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

More from Scrip

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.